A RARE CASE: RIFAMPIN-INDUCED THROMBOCYTOPENIA

Authors : Oğuzhan Satılmış, Melis Gülsar Çaycı, Atakan Tekinalp, Sinan Demircioğlu

Pages : 1316-1321

Doi:10.54005/geneltip.1673547

View : 41 | Download : 164

Publication Date : 2025-12-31

Article Type : Other Papers

Abstract :Aims: Immune thrombocytopenia (ITP) is a hematological disorder characterized by symptoms such as oral bleeding, petechiae, ecchymosis, and nasal bleeding. Tuberculosis remains a prevalent disease in Turkey, and rifampin is an important agent used in its treatment. Although rare, drug- induced ITP cases associated with rifampin use have been reported. This case report aims to draw attention to the possibility of thrombocytopenia developing as a result of rifampin use. Case: A 76-year-old male patient who had been receiving rifampin treatment following a diagnosis of tuberculosis presented with complaints of gum and nasal bleeding. The patient’s clinical history, physical examination, and laboratory findings were evaluated. Other possible causes of thrombocytopenia, such as pseudothrombocytopenia, myelodysplastic syndrome, and infections, were ruled out. Upon admission, the patient’s platelet count was found to be 3,000/mm³. Rifampin treatment was discontinued, and intravenous immunoglobulin (IVIG) and corticosteroid therapy were initiated. As a result of these treatments, a marked improvement in the patient’s platelet levels was observed. Conclusion: Although the risk of rifampin-induced ITP is low, it should still be taken into consideration. This case highlights the potential association between rifampin use and thrombocytopenia in a patient presenting with oral bleeding, nasal bleeding, petechiae, and purpura, and aims to inform clinicians of this possibility.
Keywords : Bağışıklık aracılı trombositopeni, ilaç yan etkisi, rifampisin tedavisinde antitüberküloz tedavi.

ORIGINAL ARTICLE URL